MCP-1/CCR2 axis inhibition sensitizes the brain microenvironment against melanoma brain metastasis progression

Development of resistance to chemo-and immunotherapies often occurs following treatment of melanoma brain metastasis (MBM). The brain microenvironment (BME), particularly astrocytes, cooperate toward MBM progression by upregulating secreted factors, among which we found that monocyte chemoattractant protein-1 (MCP-1) and its receptors, CCR2 and CCR4, were overexpressed in MBM compared with primary lesions. Among other sources of MCP-1 in the brain, we show that melanoma cells altered astrocyte secretome and evoked MCP-1 expression and secretion, which in turn induced CCR2 expression in melanoma cells, enhancing in vitro tumorigenic properties, such as proliferation, migration, and invasion of melanoma cells. In vivo pharmacological blockade of MCP-1 or molecular knockout of CCR2/CCR4 increased the infiltration of cytotoxic CD8(+) T cells and attenuated the immunosuppressive phenotype of the BME as shown by decreased infiltration of Tregs and tumor-associated macrophages/microglia in several models of intracranially injected MBM. These in vivo strategies led to decreased MBM outgrowth and prolonged the overall survival of the mice. Our findings highlight the therapeutic potential of inhibiting interactions between BME and melanoma cells for the treatment of this disease.

Automated summary

Resistance to chemo- and immunotherapies often develops in melanoma brain metastasis (MBM), with the brain microenvironment (BME) playing a role in promoting MBM progression. We found that monocyte chemoattractant protein-1 (MCP-1) and its receptors, CCR2 and CCR4, were overexpressed in MBM compared to primary lesions. We demonstrated that melanoma cells alter astrocyte secretome and induce MCP-1 expression and secretion, enhancing tumorigenic properties of melanoma cells. Pharmacological blockade of MCP-1 or molecular knockout of CCR2/CCR4 increased infiltration of cytotoxic CD8(+) T cells and attenuated the immunosuppressive phenotype of the BME, leading to decreased MBM growth and prolonged survival in mice.